A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Not Recruiting

Trial ID: NCT00726323


This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.

Official Title

A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma

Stanford Investigator(s)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology


Inclusion Criteria:

   - Histologically confirmed diagnosis of PRC with metastatic disease or bilateral
   multifocal renal tumors localized to kidneys. Measurable disease, ECOG performance
   status of
   - Adequate bone marrow reserve, hepatic, renal, and cardiovascular function.

Exclusion Criteria:

   - Radiation to >/=25% of bone marrow within 14 days of GSK1363089, more than 1 prior
   anti-cancer therapy, received prior treatment with a c-met inhibitor, brain

   - Any uncontrolled intercurrent illness,

   - Pregnant or breastfeeding,

   - HIV positive


drug: foretinib (formerly GSK1363089 or XL880)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Denise Haas

New Trial Alerts